All
MAGE-A3 Immunotherapeutic Fails to Improve DFS in NSCLC
April 3rd 2014The large phase III MAGRIT study investigating the MAGE-A3-specific vaccine GSK1572932A for patients with non-small cell lung cancer (NSCLC) will be completely halted following an interim analysis that demonstrated a lack of benefit.
FDA Panel Endorses Whole-Blood CRC Screening Tool by Narrow Margin
March 28th 2014The blood-based colorectal cancer (CRC) screening test Epi proColon passed the scrutiny of the FDA’s Molecular and Clinical Genetics advisory panel in a close 5-4 vote with 1 abstention in support of the claim that the test’s benefits outweigh its risks.
DFS Not Extended With MAGE-A3-Specific Immunotherapeutic in NSCLC
March 21st 2014The MAGE-A3-specific immunotherapeutic GSK1572932A failed to significantly extend disease-free survival (DFS) in patients with resected nonmetastatic non-small cell lung cancer (NSCLC) who tested negative for a specific gene expression signature.
mTOR Mutations in Exceptional Responder Suggest Sensitivity to Everolimus in Bladder Cancer
March 14th 2014An exceptional responder with advanced urothelial carcinoma experienced a complete radiologic response lasting 13.8 months following treatment with the combination of everolimus (Afinitor) and pazopanib (Votrient).
Earlier Prophylactic Surgery More Beneficial for BRCA1 Carriers
February 26th 2014According to a new study, physicians now have a clearer understanding of the optimum age for prophylactic oophorectomy in patients with BRCA mutations who want to reduce their risk of ovarian, fallopian tube, and breast cancer.
Ramucirumab/Docetaxel Combination Demonstrates Survival Benefit in NSCLC
February 20th 2014The second-line administration of ramucirumab in combination with docetaxel demonstrated a statistically significant improvement in overall survival (OS) and progression-free survival (PFS) compared with placebo plus docetaxel in patients with non-small cell lung cancer (NSCLC). The announcement was made Feb. 19 by Eli Lilly and Company, the company developing the agent.
MK-3475 to be Evaluated Across Wide Range of Cancers
February 7th 2014Merck announced the signing of three separate clinical collaboration agreements to evaluate the potential of MK-3475 across multiple tumor types. The agreements were signed through subsidiaries with Amgen Inc., Incyte Corporation, and Pfizer Inc.
FDA Grants Breakthrough Therapy Designation for Eltrombopag for SAA
February 5th 2014The FDA has granted a Breakthrough Therapy designation for the small molecule thrombopoietin receptor (TPOR) agonist eltrombopag (Promacta) for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.
Lenvatinib Meets Primary Endpoint in Phase III Differentiated Thyroid Cancer Study
February 3rd 2014The investigational agent lenvatinib (E7808) met its primary endpoint of progression-free survival (PFS) in the phase III SELECT trial, which compared lenvatinib to placebo in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC),according to Eisai Inc., the company that is developing the agent.
Final PALOMA-1 Results Confirm Efficacy of Palbociclib
February 3rd 2014Palbociclib plus letrozole is tolerable and more than doubles progression-free survival (PFS) for postmenopausal patients with locally advanced or newly diagnosed estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer, according to final results from the phase II PALOMA-1 trial
FDA Grants Breakthrough Therapy Designation for Dabrafenib for NSCLC
January 14th 2014The FDA has granted a Breakthrough Therapy designation to dabrafenib for its potential as a treatment for patients with metastatic BRAF V600E mutation-positive NSCLC who have received at least one prior line of platinum-containing chemotherapy.
Trametinib-Dabrafenib Combination Approved for Advanced Melanoma
January 10th 2014The combination of the MEK inhibitor trametinib (Mekinist) and the BRAF inhibitor dabrafenib (Tafinlar) has received an accelerated approval from the FDA as a treatment for patients with unresectable or metastatic melanoma who harbor a BRAF V600E or V600K mutation.
Phase I/II Data Shows Belinostat Could Provide Benefit for Patients in STS
November 27th 2013Belinostat (PXD101), in combination with doxorubicin, could provide benefit for patients with soft tissue sarcomas, according to final results from the first stage of the phase II portion of the phase I/II CLN-14 clinical trial.
Aldoxorubicin Demonstrates Benefit in Phase IIb Trial in Soft Tissue Sarcomas
November 22nd 2013Aldoxorubicin demonstrated response rates that culminated in a higher incidence of stable disease versus doxorubicin as a first-line treatment for advanced soft tissue sarcomas, according to results from an ongoing phase IIb study.